Eluxadoline: Side Effects, Uses & Monitoring

VIBERZI  is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Data source
FDA labeling via NIH DailyMed (label 7821bd40…)
Label version
current
Last reviewed
2026
Side effects

Reported adverse reactions

Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.

No structured frequency data available in current labeling. Consult the official label.

Uses

Labeled uses (from FDA prescribing information)

VIBERZI  is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Related conditions

Conditions associated with Eluxadoline in labeling

FAQ

Frequently Asked Questions

What is Eluxadoline used for?

FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.

What are the most commonly reported side effects of Eluxadoline?

Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.

Does Eluxadoline require lab monitoring?

Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Eluxadoline.

Where does this information come from?

All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.

Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.

Educational content only: The information on Symptom Database.com is for educational purposes and is not medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Read our full disclaimer.